
## clinical activity score not including CXR



Abstract S96 Graph 1

S97 IS AN INCREASED TENDENCY TO CLOT A RISK FACTOR FOR DEVELOPING IDIOPATHIC PULMONARY FIBROSIS?

doi:10.1136/thoraxjnl-2012-202678.102

<sup>1</sup>V Navaratnam, <sup>1</sup>A Fogarty, <sup>1</sup>T McKeever, <sup>2</sup>N Thompson, <sup>2</sup>RG Jenkins, <sup>3</sup>SR Johnson, <sup>4</sup>G Dolan, <sup>5</sup>M Kumaran, <sup>5</sup>K Pointon, <sup>1</sup>RB Hubbard. <sup>1</sup>Division of EpidemiologyPublic Health, University of Nottingham, Nottingham, United Kingdom; <sup>2</sup>Nottingham Respiratory Research Unit, Nottingham, United Kingdom; <sup>3</sup>Division of Therapeutics and Molecular Medicine, University of Nottingham, Nottingham, United Kingdom; <sup>4</sup>Department of Haematology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; <sup>5</sup>Department of Radiology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom

**Background** The aetiology of idiopathic pulmonary fibrosis (IPF) remains poorly understood. Recent animal studies and epidemiological data have suggested that activation of the coagulation cascade in the lung may have an important role in the pathogenesis of IPF.

**Methods** We recruited incident cases of physician diagnosed IPF from five teaching hospitals and eight district general hospitals in England and Wales. Age and sex matched general population controls were recruited from the same region. Participants were asked for details of lifetime occupational history, current or previous illnesses, medication and smoking. Each case and control then had a venous blood sample taken for a thrombophilia screen, including inherited and acquired clotting defects. We also collected high resolution computed tomography (HRCT) scans for all cases, which were reviewed by two experienced thoracic radiologists to confirm

the diagnosis of IPF. After excluding individuals on warfarin, logistic regression was used to estimate odds ratios for the association between a prothrombotic state and IPF, adjusting for age, sex and highly sensitive C Reactive Protein (hsCRP). Individuals were defined as being prothrombotic if they had at least one clotting defect present. The analysis was then repeated, stratifying cases by radiological diagnosis.

**Results** Our study included 306 incident cases of IPF(mean age at diagnosis 72.6 years, 70.6% male) and 256 controls (see Table 1). We found an increased tendency to clot among our cases (Odds Ratio [OR] 4.67; 95% Confidence Interval [CI] 3.00 to 7.23) compared to controls. After stratifying by radiological diagnosis, this association was stronger in those with definite usual interstitial pneumonia (UIP) (OR 5.86; 95% CI 3.08 to 11.15) compared to probable UIP (OR 3.47; 95% CI: 1.92 to 6.29). There was no effect modification by age, sex or hsCRP.

**Conclusion** An increased tendency to clot appears to be an independent risk factor for developing IPF. A clinical trial using one of the new, safer anticoagulants may be warranted.

S98

EARLY CLINICAL EXPERIENCE WITH PIRFENIDONE FOR IDIOPATHIC PULMONARY FIBROSIS (IPF) IN THE UK: INTERIM RESULTS FROM A UK COHORT

doi:10.1136/thoraxinl-2012-202678.103

¹H Parfrey, ²C Leonard, ³MA Gibbons, ¹E Harris, ²R Frank, ³C Sharp, ⁴RM Dew, ⁵TM Maher. ¹Papworth Hospital NHS Foundation Trust, Cambridge, UK; ²University Hospital of Manchester NHS Foundation Trust, Manchester, UK; ³Royal Devon and Exeter NHS Foundation Trust, Exeter, UK; ⁴PH Associates Ltd, Marlow, UK; ⁵Royal Brompton and Harefield NHS Foundation Trust, London, UK

**Introduction and Objectives** In March 2011, the novel antifibrotic, pirfenidone (Esbriet®), became the first drug to be licenced in Europe for the treatment of IPF. Since September 2011 pirfenidone has been available in the UK through a named patient programme (NPP). We present initial findings from a real-world study describing clinical experience with pirfenidone in routine UK clinical practise.

**Methods** A multi-centre, retrospective, cohort review was undertaken across 4 NHS Trusts. Data (through to July 2012) were collected from the clinical records of individuals receiving pirfenidone for IPF through the NPP.

**Results** Data was available from 68 patients (72% Male). Mean (±S.D.) age at diagnosis was 67.3±8.1 years. At initiation of pirfenidone FVC was 69.4±21.5% predicted and DLco 39.8±15.3% predicted. Domiciliary oxygen was being administered to 38.2% (26/68).

Abstract S97 Table 1

Table 1: Demographic features of incident cases of IPF and matched general population controls

		Cases (n=306)	Controls (n=256)
Mean age (standard deviation)		72.6 (8.5)	70.9 (9.0)
Number of men (%)		216 (70.6)	189 (73.8)
Smoking status (%)	Never smoked	85 (27.8)	113 (44.1)
	Ex-smokers	194 (63.4)	119 (46.5)
	Current smokers	27 (8.8)	24 (9.4)
Previous venous thromboembolic event (%)		34 (11.1)	15 (5.9)
Anticoagulant status (%)	Never been on warfarin	258 (84.3)	239 (93.4)
	Previously been on warfarin	21 (6.9)	11 (4.3)
	Currently on warfarin	27 (8.8)	6 (2.3)

A48 Thorax 2012;**67**(Suppl 2):A1–A204

At day 15, following a 14-day titration period, 92.3% (60/65) were receiving the recommended dose of 2403 mg/day pirfenidone. One patient had discontinued treatment. Data was available for 53 patients at 3 months; 42 (79.2%) continued to receive pirfenidone, whilst 11 (20.8%) had stopped therapy. Between 3 and 6 months, 93.1% (27/29) continued pirfenidone with only 2 further patients (6.9%) stopping treatment.

Of the 68 patients, 30 (44.1%) experienced an adverse drug reaction (ADR) resulting in a change of dose or cessation of pirfenidone. The commonest ADRs were GI-upset and photosensitive rash. Of those experiencing ADRs, with data available, 12/22 (54.5%) continued pirfenidone after a dose-reduction. In 53 patients for whom pre-treatment liver function tests were available, only two showed a minor increase above the upper limit of normal. During the observation period 10.3% (7/68) of patients suffered an acute exacerbation. Collection of data to determine effect of pirfenidone on lung function at 6 months of treatment is on-going.

**Conclusions** Patients enrolled in the NPP are demographically representative of the UK IPF population but have moderately severe disease that is on average more advanced than that seen in the CAPACITY study. Pirfenidone treatment is reasonably well tolerated. On-going observation of patients enrolled in the UK NPP should provide invaluable insights into the real-world benefits of pirfenidone in individuals with IPF.

S99

## A PROSPECTIVE EVALUATION OF SERIAL LUNG FUNCTION IN A UK COHORT OF PATIENTS WITH LYMPHANGIOLEIOMYOMATOSIS (LAM)

doi:10.1136/thoraxjnl-2012-202678.104


<sup>1</sup>V Navaratnam, <sup>2</sup>O Gbolahan, <sup>1</sup>RB Hubbard, <sup>2</sup>SR Johnson. <sup>1</sup>Division of Respiratory Medicine, University of Nottingham, Nottingham, UK; <sup>2</sup>Division of Therapeutics and Molecular Medicine, University of Nottingham, National Centre for Lymphangioleiomyomatosis, Nottingham, UK

**Background** LAM is a rare disease of women in which abnormal smooth muscle cells invade and destroy particularly the lungs and lymphatics. We wanted to relate the progression of the disease with presenting clinical features and to determine rate of decline of lung function in patients to improve prognostic predictions and stratify patients for clinical trials.

**Methods** Clinical features and pulmonary function test (PFT) data were collected from 125 patients with a definitive diagnosis of LAM by European Respiratory Society Criteria receiving care at the National Centre for LAM. Ethical approval for use of patient data was obtained and patients gave informed consent. 74 of these patients with more than two sets of PFTs formed the prospective cohort. Patients were grouped into degree of lung function impairment based on FEV $_{\rm l}$  or DL $_{\rm CO}$  at first presentation: unimpaired; PFTs >80% predicted, mild; 61%-80%, moderate; 40%–60%, severe; <40%.

**Results** The median follow-up period was 28.5 months (range 3–262). PFTs declined as the disease progressed (figure shows all prospective FEV $_1$  measurements from presentation). Mean changes for FEV $_1$  were –49.68 ml/yr, FVC –44 ml/yr, and DL $_{\rm CO}$  –0.07 mmol/min/kPa/yr. Rate of change in FEV $_1$  varied between patients with different degrees of lung function impairment at first presentation with change in FEV $_1$  within the groups being: unimpaired –84 ml/yr, mild –32 ml/yr, moderate –59 ml/yr and severe –24 ml/yr.

**Conclusion** The rate of decline of FEV1 in this cohort was slower than in previous retrospective studies of patients with LAM. Change in  $\text{FEV}_1$  varied with degree of lung function impairment being more rapid in those with early disease ie. well preserved lung function at diagnosis. Clinical features at onset may be associated with rate of progression of LAM. These data may be helpful in advising patients on prognosis and designing clinical trials.



Abstract S99 Figure 1

S100

NATURAL HISTORY OF RENAL ANGIOMYOLIPOMA
IN SPORADIC AND TUBEROUS SCLEROSIS COMPLEX
ASSOCIATED LYMPHANGIOLEIOMYOMATOSIS:
IMPLICATIONS FOR CLINICAL CARE

doi:10.1136/thoraxinl-2012-202678.105

ZW Yeoh, V Navaratnam, RB Hubbard, SR Johnson. Therapeutics and Molecular Medicine, Respiratory Medicine and National Centre for LAM, University of Nottingham, Nottingham, UK

**Background** Lymphangioleiomyomatosis (LAM) is a rare disease of women categorised by lung cysts, lymphatic abnormalities and angiomyolipomas; a benign tumour occurring chiefly in the kidneys. Although benign, the tumours can enlarge causing symptoms and those over 4cm are prone to haemorrhage which can result in nephrectomy. LAM can occur in isolation (sporadic LAM) or associated with tuberous sclerosis complex (TSC-LAM). Treatment guidelines for angiomyolipoma tend to be based on retrospective series often from patients with TSC. The natural history of angiomyolipoma in sporadic LAM is not well understood.

**Aims** To document the natural history, risk factors for, and clinical features associated with, angiomyolipoma in a national cohort of patients with sporadic and TSC-LAM to plan clinical screening programs.

**Methods** Demographic data, clinical features, lung function and tumour size were obtained from clinical records of patients attending the National Centre for LAM in Nottingham. Tumour size was recorded as the longest tumour diameter on any imaging modality. Tumours smaller than 10mm were assigned a value of 10mm. Ethical approval for use of patient data was obtained and patients gave informed consent.

Results 122 patients with definite or probable LAM by European Respiratory Society criteria were identified. Of these, 68 (56%) had at least one angiomyolipoma. Angiomyolipoma were present in 50% of patients with sporadic LAM and all patients with TSC-LAM. Those with sporadic LAM tended to have smaller tumours than those with TSC-LAM (31mm (SD 27) vs. 49mm (SD 27) respectively), were less often bilateral (40 vs. 79%), were less likely to bleed (17 vs. 31%) and less likely to require surgery or embolisation (49 vs. 66%). Serial tumour measurements were available from some patients, tumours from those with TSC-LAM grew at 3.8 mm/year (n=6, SD 14.2) tumour growth in sporadic LAM growth was 4.3 mm/year (n=16, SD 8.2. p=0.46).

**Conclusions** Angiomyolipomas are common in patients with sporadic and TSC-LAM. The tumours require intervention more frequently in TSC than sporadic LAM. The two patient groups may require different angiomyolipoma management.